Advancell researches a drug for treating the most frequent chemotherapy disorders Blog Post

The biotech company – specialized in nanomedicine and cell methods for in vitro research, and located at the Barcelona Science Park- has signed an agreement with the company Nobera Pharma for the development of a drug aimed at treating palmar-plantar erythrodysesthesia, also known as the hand-foot syndrome, a very frequent side effect in cancer patients which leads to the reduction and even interruption of chemotherapy, decreasing possibilities for survival.